Gilead Sciences, Inc. (GILD)

Gilead Sciences Product Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021
HIV	19.86B	19.61B	18.85B	18.45B	18.33B	18.18B	18.26B	18.08B
HIV Growth	8.34%	7.90%	3.28%	2.06%	3.68%	5.71%	7.64%	8.48%
Oncology	3.26B	3.29B	3.21B	3.16B	3.05B	2.93B	2.78B	2.59B
Oncology Growth	6.75%	12.18%	15.46%	22.16%	27.71%	37.07%	47.77%	59.19%
Liver Disease	3.04B	3.02B	2.99B	2.97B	2.85B	2.78B	2.79B	2.87B
Liver Disease Growth	6.92%	8.55%	7.43%	3.42%	0.21%	-0.57%	0.83%	8.19%
Veklury	1.55B	1.80B	2.18B	2.13B	2.17B	2.19B	2.47B	2.75B
Veklury Growth	-28.70%	-17.71%	-11.52%	-22.84%	-26.37%	-44.05%	-42.16%	-47.64%
Other	874.00M	889.00M	906.00M	921.00M	884.00M	859.00M	910.00M	894.00M
Other Growth	-1.13%	3.49%	-0.44%	3.02%	-2.54%	-9.00%	-3.40%	-9.42%

Revenue by Type

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Product	28.58B	28.61B	28.14B	27.62B	27.28B	26.93B	27.20B	27.18B
Product Growth	4.77%	6.22%	3.48%	1.63%	1.94%	-0.18%	1.44%	-0.03%
Other	158.00M	143.00M	155.00M	181.00M	175.00M	182.00M	193.00M	201.00M
Other Growth	-9.71%	-21.43%	-19.69%	-9.95%	-39.24%	-38.93%	-40.80%	-38.53%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.